80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
نویسندگان
چکیده
IMpower010 showed significant DFS benefit with atezo after adjuvant chemo in resected NSCLC (Felip Lancet 2021). At the interim analysis, significance boundary was crossed for stage II-IIIA PD-L1 TC ≥1% population (stratified HR, 0.66; 95% CI: 0.50, 0.88), greatest ≥50% subgroup (unstratified 0.43; 0.27, 0.68). Here we present further analyses pts. (NCT02486718) study design and primary analysis details have been reported (VENTANA SP263 assay) (UICC/AJCC v7) pts a prespecified secondary endpoint; additional data are exploratory. Baseline characteristics were generally balanced atezo- vs BSC-arm (male, 77% 68%; III, 46% 50%; nonsquamous, 59% 61%). Median follow-up 34.2 mo (21 Jan 2021 cutoff). See table data. Safety consistent that of overall known safety profile atezo. Initial disease relapse this locoregional-only 15/25 atezo-arm (60%) 17/50 (34%) distant-only 6/25 (24%) 21/50 (42%); initial CNS-only seen 1/25 (4%) 7/50 (14%). 19 relapsing (76%) 30 had subsequent systemic therapy (mostly chemo, 60% 32%; immunotherapy, 16% 38%). derived BSC at analysis. Data across most subgroups, albeit limited pt numbers post hoc Numerically, more distant CNS relapses BSC. The tolerability line population, demonstrating positive benefit-risk profile.Table: 80OInterim DFS: II-IIIAPts, nUnstratified HR (95% CI)AtezoBSCAge <65 y ≥65 y71 4470 440.49 (0.27, 0.89) 0.36 (0.17, 0.75)Sex Male Female89 2678 360.50 (0.28, 0.34 (0.15, 0.76)Histology Squamous Nonsquamous47 6845 690.60 (0.29, 1.26) (0.20, 0.65)Stage II IIIA62 5357 570.51 (0.26, 1.00) 0.38 0.72)Regional LN N0 N1 N230 43 4221 52 411.09 (0.39, 3.07) 0.29 (0.12, 0.72) 0.35 (0.18, 0.68)Smoking status Current/former Never99 1699 150.40 (0.24, 0.68) 0.46 1.25)EGFR/ALK mutation Detected Undetected Unknown9 5411 54 490.26 (0.06, 1.02) 0.41 0.84) 0.45 (0.23, 0.91)DFS event/pts: atezo, 28/115 (24%); BSC, 52/114 (46%). Open new tab
منابع مشابه
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.
BACKGROUND Cetuximab-induced hypomagnesemia has been associated with improved clinical outcomes in advanced colorectal cancer (CRC). We explored this relationship from a randomized clinical trial of cetuximab plus best supportive care (BSC) versus BSC alone in patients with pretreated advanced CRC. PATIENTS AND METHODS Day 28 hypomagnesemia grade (0 versus ≥1) and percent reduction (<20% vers...
متن کاملThe impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective
BACKGROUND The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. OBJECTIVES 1- Design a sliding scale to grade survival in 2nd-line non-small-cell lung cancer (NSCLC). 2- Compare costs and value of Nivolumab (Nivo), Atezolizumab (Atezo) and Pembrolizumab (Pembro) vs. Docetaxel (Doc). METHODS Pre...
متن کاملStructural basis of the therapeutic anti-PD-L1 antibody atezolizumab
Monoclonal antibodies targeting PD-1/PD-L1 signaling pathway have achieved unprecedented success in cancer treatment over the last few years. Atezolizumab is the first PD-L1 monoclonal antibody approved by US FDA for cancer therapy; however the molecular basis of atezolizumab in blocking PD-1/PD-L1 interaction is not fully understood. Here we have solved the crystal structure of PD-L1/atezolizu...
متن کاملYAP regulates PD-L1 expression in human NSCLC cells
Programmed death-ligand 1 (PD-L1) is a membrane protein on tumor cells that binds to the PD-1 receptor expressed on immune cells, leading to the immune escape of tumor cells. Yes-associated protein (YAP) is a main effector of the Hippo/YAP signaling pathway, which plays important roles in cancer development. Here we show that YAP regulates PD-L1 expression in human non-small cell lung cancer (N...
متن کاملLba9 Pr Association between Tumor Egfr and Kras Mutation Status and Clinical Outcomes in Nsclc Patients Randomized to Sorafenib plus Best Supportive Care (bsc) or Bsc Alone: Subanalysis of the Phase Iii Mission Trial
book and program 642 NOTCH AND DLL4 EXPRESSION IN BEVACIZUMAB-TREATED COLON CANCER PATIENTS 646 PHASE II STUDY OF S-1 PLUS LEUCOVORIN (1 WEEK TREATMENT REGIMEN FOLLOWED BY 1 WEEK REST PERIOD) IN PATIENTS WITH UNTREATED METASTATIC COLORECTAL CANCER IN JAPAN AND CHINA: COMPARING RESULTS OF EACH COUNTRY AND UPDATING OVERALL SURVIVAL 651 RETROSPECTIVE ANALYSIS OF PATHOLOGICAL RESPONSE IN COLORECTAL...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2022
ISSN: ['0923-7534', '1569-8041']
DOI: https://doi.org/10.1016/j.annonc.2022.02.090